Ultrasensitive Human Immunodeficiency Virus Type 1 Viral Load as a Marker of Treatment Choice for Simplification Strategies | Zendy

Sidonie Lambert-Niclot | Zendy; Maxime Grudé | Zendy; JeanLuc Meynard | Zendy; AnneGeneviève Marcelin | Zendy; MarcAntoine Valantin | Zendy; Philippe Flandre | Zendy; Jacques Izopet | Zendy; Laëtitia Moinot | Zendy; Vincent Bouteloup | Zendy; Vincent Cálvez | Zendy; Christine Katlama | Zendy; PierreMarie Girard | Zendy; Laurence MorandJoubert | Zendy

Open Access

Ultrasensitive Human Immunodeficiency Virus Type 1 Viral Load as a Marker of Treatment Choice for Simplification Strategies

Author(s) -

Sidonie Lambert-Niclot,

Maxime Grudé,

JeanLuc Meynard,

AnneGeneviève Marcelin,

MarcAntoine Valantin,

Philippe Flandre,

Jacques Izopet,

Laëtitia Moinot,

Vincent Bouteloup,

Vincent Cálvez,

Christine Katlama,

PierreMarie Girard,

Laurence MorandJoubert

Publication year - 2018

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciy382

Subject(s) - medicine , virology , viral load , human immunodeficiency virus (hiv) , viral disease , virus , sida , lentivirus , immunology

Using 3 randomized Protease inhibitor (PI) monotherapy studies: Kalesolo, Dream and Monoi, we performed a pooled-analysis. Our objective was to determine in PI monotherapy and standard tritherapy: 1) distribution of ultrasensitive viral load (USVL) at week 96 (W96); 2) factors associated with virological failure (VF) at W96 and 3) factors associated with USVL<1 copy at W96.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research